Navigation Links
Avastin Boosted Survival for Type of Aggressive Breast Cancer: Study
Date:12/7/2011

WEDNESDAY, Dec. 7 (HealthDay News) -- In November, the U.S. Food and Drug Administration revoked its approval of the drug Avastin for the treatment of breast cancer. But, a new study suggests that the drug can boost the survival of women with a specific type of aggressive breast tumor when used in conjunction with two other medications.

Avastin (bevacizumab) had been approved in the United States in 2008 as a treatment for metastatic breast cancer -- cancer that has spread to other parts of the body. It was used with chemotherapy to treat a type of breast tumor called HER2-negative.

Even though the FDA withdrew that approval, Avastin is still approved to treat some other types of cancers. Doctors may legally prescribe the drug to treat breast cancer, although insurers may refuse to cover it.

According to the FDA, the benefits of Avastin use for breast cancer do not justify the risks, which may include severe high blood pressure, bleeding, and heart attack or heart failure.

The new study was funded by Genentech, which makes Avastin, and led by Dr. Luca Gianni, director of medical oncology at the San Raffaele Cancer Center in Milan, Italy. They examined the use of the drug as a treatment for HER2-positive breast cancer that had recurred locally in the body or spread to other parts of the body. HER2-positive breast cancers are typically less sensitive to standard hormonal treatments and are often more aggressive than other types.

A total of 216 patients received Avastin with a chemotherapy treatment of trastuzumab (Herceptin) and docetaxel, while 208 received the chemotherapy alone.

An investigator and an expert review committee disagreed about how much of a difference the drug made in the risk of cancer progression or death. But overall, according to investigator and independent review committee analysis, the addition of the Avastin boosted the average months of survival (without worsening of the cancer) by nearly three months, the researchers said.

Dr. Hannah M. Linden, an oncologist and associate professor of medicine at the University of Washington in Seattle, called the research "exciting."

"I am delighted that further analysis will be done to try to determine which tumors respond to each therapy, and really which tumors do not need extra treatment," Linden said. "With HER 2-positive tumors, we have a plethora of options and need to learn to be efficient in maximizing benefit to patients and minimizing toxicity."

The study is scheduled for presentation this week at the 2011 San Antonio Breast Cancer Symposium. The data and conclusions of research presented at medical meetings should be viewed as preliminary until published in a peer-reviewed journal.

More information

The U.S. National Library of Medicine has more about breast cancer.

-- Randy Dotinga

SOURCES: Hannah M. Linden, M.D., oncologist and associate professor of medicine, University of Washington, Seattle; San Antonio Breast Cancer Symposium, news release, Dec. 7, 2011


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. FDA Revokes Approval of Avastin for Breast Cancer
2. Clinical trial shows benefit to adding avastin to neoadjuvant chemotherapy in breast cancer patients
3. Avastin Rejection Supported by Cancer Experts
4. FDA Panel Rejects Avastin for Breast Cancer
5. Cancer Drug Avastin Makes Inroads Against Ovarian Tumors
6. NIH study finds Avastin and Lucentis are equally effective in treating AMD
7. More Evidence Cancer Drug Avastin May Cause Harm
8. More Evidence Links Avastin to Heart Failure in Breast Cancer Patients
9. FDA Advises Against Avastin as Treatment for Breast Cancer
10. FDA Advisers Say Avastin Shouldnt Be Used for Breast Cancer
11. Avastin Largely Safe for Patients With Type of Advanced Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Avastin Boosted Survival for Type of Aggressive Breast Cancer: Study
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... June 19, ... the dangers associated with chronic pain and the benefits of holistic treatments, Serenity ... who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, ... Elite. The attorneys chosen by their peers for this recognition are considered among the ... Traurig Shareholders received special honors as members of this year’s Legal Elite Hall of ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway ... call for a minimum wage raise to $12 an hour by 2020 and then adjusting ... restore the lost value of the minimum wage, assure the wage floor does not erode ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... Living, is proud to recognize Dr. Barry M. Weintraub as a prominent plastic ... most beautiful women in the world, and the most handsome men, look naturally ...
(Date:6/24/2016)... ... June 24, 2016 , ... National recruitment firm Slone ... executive with extensive sequencing and genomics experience, as Vice President of North American Capital ... will be responsible for leading the sales team in the commercialization of the HTG ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Research and Markets has announced the ... report to their offering. ... favourable commercial environment for MedImmune to enter. The US ageing ... serve to drive considerable growth for effective anti-influenza medications. The ... sales considerably, but development is still in its infancy. ...
(Date:6/23/2016)... RIDGE, Ill. and INDIANAPOLIS ... of students receiving a Lilly Diabetes Tomorrow,s Leaders Scholarship ... The 2016 scholarship winners, announced today online at ... to let type 1 diabetes stand in the way ... Diabetes has supported the Foundation,s scholarship program since 2012, ...
(Date:6/23/2016)... N.J. , June 23, 2016  Guerbet announced ... Premier Inc.,s Supplier Horizon Award . ... year, Guerbet was recognized for its support of Premier ... creation through clinical excellence, and commitment to lower costs. ... to receive this recognition of our outstanding customer service ...
Breaking Medicine Technology: